Investigating Non-response to Cardiac Resynchronisation: Evaluation of Methods to Eliminate Non-response and Target Appropriate Lead location in patients with Coronary Artery Disease

niversity of Calgary (Canada)0 个研究点目标入组 300 人开始时间: 2008年6月17日最近更新: 2019年3月18日

适应症

试验速览

暂无简介。

•1. Left ventricular ejection fraction (LVEF) less than or equal to 0.35 measured within three months of enrolment
•2. Specific Activity Scale (SAS) class 3 or 4 symptoms (moderate to severe functional capacity limitation due to heart failure) within 1 month of enrolment
•3. QRS width greater than 120 ms
•4. Confirmed dyssynchrony on screening echo
•5. Documented history of ischaemic heart disease (prior myocardial infarction, prior coronary artery bypass, prior coronary angioplasty, or imaging confirmation [angiogram, cardiac MRI])
•6. On stable doses of angiotensin converting enzyme (ACE) inhibitor or angiotensin II blocker and a beta-blocker for greater than or equal to two months unless medically contra-indicated
•7. Controlled heart rate if in permanent atrial fibrillation (AF) (resting rate less than 70 and maximal rate less than 120 bpm)
•8. Patients aged 18 years or older

•1. Unable or unwilling to provide informed consent
•2. Medical condition other than heart failure likely to cause death within 12 months
•3. Cardiac transplant planned within six months
•4. Known contra-indication to transvenous CRT device implant (e.g., active sepsis, artificial tricuspid valve, known vascular occlusion that will prevent delivery of transvenous leads)
•5. Clinically significant myocardial infarction within last two months
•6. Coronary artery bypass graft surgery less than or equal to two months or coronary angioplasty less than or equal to one month

发起方

niversity of Calgary (Canada)